Previous studies have suggested that thyroid function is associated with breast cancer risk, which could have an important clinical impact, as one in eight women will develop a thyroid disorder during her lifetime. However, the underlying pathomechanism behind the association is still unknown. We used the Malm€ o Diet and Cancer Study (a population-based prospective study consisting of 17,035 women) to examine 17 single nucleotide polymorphisms (SNPs) previously related to levels of free thyroxine (free T4) and thyroid peroxidase antibodies (TPO-Ab) as potential genetic risk factors for breast cancer. A baseline examination including free T4 and TPO-Ab levels was conducted at the time of inclusion. Genotyping was performed on 901 breast cancer patients and 3335 controls. Odds ratios (95% confidence intervals) for high free T4, TPO-Ab positivity, and breast cancer were calculated by logistic regression and adjusted for confounders. We identified one free T4-related SNP (rs2235544, D101 gene) that was significantly associated with both free T4 level and breast cancer risk. There was a suggested association between rs11675434 (TPO gene) and TPO-Ab level, and TPO-Ab-related rs11675434 (TPO), rs3094228 (HCP5), rs1033662 (no registered gene), and rs301806 (RERE) were associated with breast cancer risk. There was an indicated interaction between rs6485050 (no registered gene) and free T4 level in regards to breast cancer risk. This is the first study to suggest an association between thyroid-related SNPs and breast cancer risk. All SNPs have a biological plausibility of being associated with breast cancer risk, and may contribute to the genetic predisposition to breast cancer.
have been shown to mimic the effects of the estrogens by stimulating the estrogen receptor, a factor that is associated with increased breast cancer risk. 7 Also, thyroid peroxidase (TPO), an enzyme involved in thyroid hormone synthesis, 8 has been found to be expressed in breast cancer cells. 9 Moreover, in two previous studies, we have shown that thyroid hormone free thyroxine (fT4) and TPO-antibodies (TPO-Ab) may be associated with breast cancer risk and survival following breast cancer, and that the commonly prescribed medication Levothyroxine (synthetic T4) therefore could have the potential of affecting breast cancer survival. 10, 11 However, even if the majority of earlier prospective studies have pointed toward an association, previous studies are still inconsistent and the potential underlying pathomechanism is unknown. 12 Interestingly though, to our knowledge the association between thyroid-related SNPs and breast cancer risk have not previously been evaluated.
Therefore, through a literature and database search, we identified 17 candidate SNPs associated with fT4 and TPOAb that existed on the Illumina HumanOmniExpress-Exome BeadChip. 13 In this study, we examined the associations of these SNPs on a homogenous Caucasian population in the Malm€ o Diet and Cancer Study (a population-based prospective study consisting of 17,035 women from the same Swedish city), through logistic regression analysis. In a main analysis, we subsequently assessed the association between these SNPs and breast cancer risk on 901 breast cancer patients and 3335 controls. In an explorative analysis, we also studied the potential interaction between fT4 and TPO-Ab levels and related SNPs with regard to breast cancer risk. The aim of this prospective nested case-control study was to examine if SNPs related to fT4 levels and TPO-Ab levels are associated with breast cancer risk, with the purpose of identifying potential novel genetic markers for breast cancer, and to further evaluate the relationship between thyroid function and breast cancer risk.
Methods

The Malm€ o Diet and Cancer Study
The Malm€ o Diet and Cancer Study (MDCS) is a populationbased prospective study, including 17,035 women. 14 
Identification of breast cancer cases and controls
Patients with incident invasive and cancer in situ (CIS) breast cancer were identified by record-linkage with the highly accurate Swedish Cancer Registry and the Southern Swedish Regional Tumour Registry, 15, 16 A total of 3362 controls were retrieved from the MDCS. Out of these, 704 controls were selected from a previous study, where they were matched to breast cancer patients using incidence density matching based on age at inclusion, calendar time at inclusion and menopausal status at baseline. 17 An additional 2658 controls were randomly selected among females without a breast cancer diagnosis and who were part of a randomized subsample of the MDCS, the MDCS Cardiovascular Cohort (MDC-CC). 18 Forty-five of the patients and 27 of the controls did not have sufficient biological material for genotyping. Hence, 901 out of 946 patients and 3335 out of 3362 controls were potentially eligible for this study ( Figure 1 ).
Genotyping
DNA was extracted from the stored blood samples. Genotyping was performed using the HumanOmniExpressExome BeadChip (OEE) version 1.0 or 1.1 Ch37 and iScan System (Illumina, San Diego, CA, USA) at the Broad Institute of MIT and Harvard, USA, and at the Clinical Research Center (CRC), Malm€ o, Sweden. 19 The OEE chip included 244 194
primarily exonic markers and 706 924 markers for coverage of common genome-wide variation. 20 Genotyping was conducted at Broad Institute for 804 out of the 901 patients, and for 3244 out of the 3335 controls. For the remaining 97 patients and 91 controls genotyping was performed at CRC.
What's new?
Thyroid function is potentially associated with breast cancer risk, a disease for which a significant proportion of genetic susceptibility remains unknown. Here, genetic markers for thyroid hormone and thyroid peroxidase antibody levels were used to investigate potential associations between thyroid function and breast cancer risk. Several single nucleotide polymorphisms (SNPs), located near genes related to thyroid and immune function, were associated with breast cancer risk. Among the identified SNPs was rs2235544 (D101 gene), a variant associated with free thyroxine levels and breast cancer risk. The findings warrant further exploration to help clarify links between thyroid function and breast cancer.
Quality control and exclusion of relatives
Quality control (QC) in subjects included control for call rate >95% and inbreeding coefficients of 202 to 0.2 to control for excess of heterozygosity, 19 excluding 14 of the patients and 37 of the controls (Figure 1 ). By use of identity by descent sharing relatives of first and second degree were identified, and the relative with the lowest call rate was omitted, excluding another 22 patients and 105 controls. Hence, after QC and exclusion of relatives 865 patients and 3193 controls remained in the study.
During QC of SNPs, 169,775 SNPs were excluded, due to lack of variation in European population (monomorphic SNPs) or due to deviation from Hardy Weinberg equilibrium in controls (p < 10 26 ) or due to variant call rate of <95% in all samples. This resulted in approximately 750,000 SNPs remaining after quality control. All QC was performed with the use of PLINK version 1.07 software.
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Candidate SNP selection
Identification of SNPs related to fT4 levels and TPO-Ab levels was performed through the GWAS Catalog. 13 This resulted in 9 SNPs related to fT4 levels, and 14 SNPs related to TPO-Ab levels from three different papers (Figure 2 ). [22] [23] [24] Two of these studies were large meta-analyses performed on a European population, of which Medici et al. identified TPO-Ab-related SNPs and Porcu et al. discovered fT4-related SNPs. The study by Kwak et al. found both TPO-Ab-related and fT4-related SNPs in 4238 Asian subjects.
Out of the 9 SNPs previously associated with fT4 levels, one had only shown an association on males (rs6499766), and was therefore excluded in this study. Of the remaining SNPs, three related to fT4 levels and six related to TPO-Ab levels were not included on the OEE chip. SNAP Proxy 25 was used to identify SNPs with a linkage disequilibrium (LD) of r2 > 0.8 to the missing SNPs, resulting in one SNAP proxy for one SNP related to fT4 and three SNAP proxies for three SNPs related to TPO-Ab levels. However, two SNPs related to fT4 level (rs7045138, rs7860634) and three SNPs related to TPO-Ab (rs10944479, rs1230666 and rs733208) were neither on the OEE chip nor had any SNAP proxies with r2 > 0.8 on the chip, and these SNPs were therefore excluded in this study.
In all, the final analysis included 11 SNPs related to TPOAb level ( 
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Kwak et al.; Figure 2 ). All selected SNPs had a minor allele frequency (MAF) >5%.
Laboratory analysis for fT4 and TPO-ab
At the baseline examination, blood was collected from all subjects in this study. Serum was stored in a biological bank at 2808C, with a storage time between 14 and 19 years from baseline until analysis of TPO-Ab and fT4. Plasma levels of TPO-Ab and fT4 were measured on a subset of patients and controls as part of a previous study during July 2009. 12 The laboratory analysis was performed with Beckman Access
Immunoassay System on a UniCel TM Dx1800 (Beckman Coulter Inc, Brea, CA, USA). TPO-Ab was considered "positive" when values were above 9.0 kIU/L, according to the manufacturer. For fT4, the normal range was 8-14 pmol/ L. Out of the 865 cases and 3193 controls, data on fT4 and TPO-Ab were available for 606 cases and 583 controls.
Statistical analysis
The genome association analysis toolset PLINK version 1.07 software 21 was used to extract the selected SNPs from the dataset, and to calculate minor allele and major allele and MAF for the SNPs. All alleles were converted to forward strand. The statistical analysis was performed using SPSS version 23 (SPSS, Chicago, IL, USA). Patients and controls were described regarding established and potential risk factors for breast cancer, Table 1 . For this description of the cohort, all individuals were included (901 cases and 3335 controls). Missing values were coded as a separate category for all variables.
For the statistical analysis, the 4058 individuals (865 cases, 3193 controls) remaining after quality control and exclusion of relatives were included. SNPs were divided into three genotype categories and additive effects were tested. Homozygote for major allele was used as a reference for all SNPs. All subsequent analyses were performed via logistic regression, and the definition for statistical significance was odds ratios (ORs) with 95% confidence intervals (CIs) and a p value of <0.05. All ORs that were very close to these levels but not statistically significant were defined as suggested or indicated associations in the subsequent results section.
In the first statistical analysis, logistic regression was conducted to calculate odds ratios in relation to TPO-Ab levels and fT4 levels, respectively. This analysis was only performed on controls with available thyroid analyte levels (n 5 583), to determine the physiological effect without breast cancer as a potential confounder, that is, so that the breast cancer itself would not risk affecting the thyroid analyte levels. Therefore, controls with thyroid disease (goiter) and/or thyroid medication (thyreostatics/synthetic thyroid hormone) had also been excluded in this analysis. A sensitivity analysis, including only controls genotyped at the Broad Institute of MIT and Harvard was also performed (N 5 506). Furthermore, in an additional analysis, the analysis was conducted on controls (N 5 583) and cases (N 5 606) together. For TPO-Ab, the analysis was performed as a categorical variable, and divided into negative and positive values (cutoff 9.0 kIU/L). For fT4, the analysis was conducted as a categorical dichotomized variable, with values 2.0-10.0 pmol/L considered low level and 10.1-18.6 pmol/L considered high level. Analysis was performed both unadjusted and adjusted for age at baseline, time of baseline examination (to avoid a confounding effect by different storage time of the thyroid analytes) and smoking (influences thyroid hormone levels and may increase risk of breast cancer 26, 27 ). Subsequently, logistic regression was conducted to calculate ORs with 95% CI for overall breast cancer risk (cancer in situ, invasive and bilateral breast cancer). This analysis was performed on all 865 patients and 3193 controls. In a second model, adjustment was made for established and potential confounders for breast cancer risk. To clarify and enable comparisons, both ORs with 95% CIs and p values (statistical significance limit < 0.05) were used for the adjusted per allele results. A sensitivity analysis, excluding all individuals with thyroid disease or thyroid medication, was also made. In a second sensitivity analysis, only subjects genotyped at the Broad Institute were included (N 5 3884). Moreover, a third sensitivity analysis was limited to controls (N 5 3193) and invasive breast cancer patients (N 5 771). The logistic regression analysis for breast cancer risk was also performed stratified on TPO-Ab and fT4-level, respectively. The stratified analysis was made on breast cancer cases (N 5 606) and controls (N 5 583) with available thyroid analyte levels, excluding individuals with thyroid disease and/or thyroid medication. To further test if TPO-Ab level/fT4 level were effect modifiers, an interaction analysis on SNP and thyroid analyte level was conducted. In the final step, a perallele analysis was made for all logistic regression analysis, that is, with genotype as a continuous variable instead of as a categorical variable.
Genetic risk score and variation analysis
The variants were selected from 3 different papers (one with fT4-related SNPs on a European population, one with TPOAb-related SNPs on a European population and one with both fT4 and TPO-Ab-related SNPs on an Asian population). [22] [23] [24] For the genetic risk score analysis, only the papers conducted on a European population were included, 22, 24 as
SNPs may differ between populations. Hence, a weighted genetic risk score (wGRS) was created for TPO-Ab-related SNPs and fT4-related SNPs, respectively, based on the beta coefficients and odds ratios in the original papers. Percentages of variation were calculated with Nagelkerke Rsquare.
Results
Established and potential risk factors for breast cancer in controls and breast cancer patients
The mean time from baseline examination to a breast cancer diagnosis was 8.37 years (standard deviation 4.48 years).
Patients had a higher level of education and less manual work compared to women in the control group (Table 1) . A higher percentage of these women had taken oral contraceptives but less had taken hormonal replacement therapy, compared to patients. Controls were more often peri-or postmenopausal at the time of inclusion than cases.
SNPs in relation to TPO-ab levels
For two TPO-Ab-related SNPs rs11675434 (TPO gene) and rs8048539 (Not Registered 5 NR gene), there was a suggested association toward TPO-Ab positivity in T allele carriers compared to the CC genotype ( Table 2 ). The other SNPs showed no association with TPO-Ab levels in our study. All results were similar in the analysis only performed on controls, and in the analysis conducted on both breast cancer cases and controls. In the sensitivity analysis including only controls genotyped at the Broad Institute, the results in the per allele analysis on TPO-Ab status became statistically significant for rs11675434 (TPO gene), with a crude OR of 1.40 (95% CI 1.03-1.90), all other results were similar to the main analysis.
SNPs related to TPO-ab levels in relation to breast cancer risk
The two SNPs associated with the TPO-Ab levels in our study (rs11675434 and rs8048539) were not associated with breast cancer risk in the non-stratified analysis, Table 2 . However, two other SNPs, rs3094228 (HCP5 gene) and rs1033662 (NR gene), showed some association with the risk. For both variants, only the heterozygous genotype was associated with decreased breast cancer risk (Table 2) . For rs2010099 (KARLN gene), the rare TT genotype was associated with a lower breast cancer risk than CC in the crude results. The sensitivity analysis, excluding all individuals with thyroid disease or thyroid medication, did not affect any of the results. The two other sensitivity analyses, including only subjects genotyped at the Broad Institute and only invasive breast cancer patients, respectively, displayed similar results to the main analysis. Cancer Epidemiology Table 2 . Crude odds ratio. 3 Odds ratio for positive TPO-Ab status adjusted for age at baseline, time of baseline examination and smoking. 4 Odds ratio and p values for breast cancer adjusted for age at baseline, menopausal status, socioeconomic index, education, marital status, country of birth, hormonal replacement therapy, oral contraception, age at menarche, parity, body mass index, alcohol consumption and smoking.
p values are only displayed for the per allele analysis.
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SNPs related to TPO-ab levels in relation to breast cancer risk, stratified by TPO-ab level
One of the two TPO-Ab level-associated SNPs in our study, rs11675434 (TPO gene), showed a stronger association between the T allele and breast cancer in TPO-Ab-negative women than in TPO-Ab-positive women ( Table 3 ). The strongest association among TPO-Ab-negative women was observed for rs301806 (RERE gene), for which the C allele carriers had an increased breast cancer risk compared to the TT genotype. Also the associations of several other SNPs with breast cancer tended to be stronger among TPO-Abnegative women than among TPO-Ab-positive women, including the SNPs rs653178 (SH2B3 and ATXN2 genes), rs3094228 (HCP5 gene), and rs9277555 (HLA-DPB1 gene).
Only for rs1033662 (NR gene) and rs2071403 (TPO gene), the associations tended to be stronger in the group of TPOAb-positive women. There were no statistically significant interactions between TPO-Ab level and SNPs in regards to breast cancer risk (data not shown).
Genetic risk score and variation in traits for TPO-abrelated SNPs
For the 10 TPO-Ab-related variants found on a European population, the wGRS showed a statistically significant association in relation to TPO-Ab levels in the 1189 cases and controls with available TPO-Ab levels (OR 1.08, 95% CI 1.03-1.14). The wGRS for TPO-Ab-related SNPs did not show a clear association between TPO-Ab positivity and breast cancer risk (OR 0.97, 95% CI 0.94-1.01). Results were similar in the analysis stratified on TPO-Ab level.
A combined wGRS of the 10 SNPs related to TPO-Ab levels explained 0.9% of the variation in TPO-Ab levels in the 1189 cases and controls with available TPO-Ab levels, 0.8% in controls and 1.1% in cases. The wGRS explained 0.1% of breast cancer risk.
SNPs in relation to fT4 levels
For SNPs previously related to fT4 levels, rs2235544 (D101 gene) was associated with lower fT4 levels when having the CC genotype compared to AA genotype (Table 4) . This was statistically significant in the crude, adjusted and per allele analysis. There were no other associations in regards to fT4 levels. All results were similar in the analysis performed on both breast cancer cases and controls to the displayed analysis performed on only controls. Also, the sensitivity analysis including only controls genotyped at the Broad Institute showed a high similarity to the main analysis.
SNPs related to fT4 levels in relation to breast cancer risk
For the SNP that was associated with fT4 level in our study, rs2235544 (D101 gene), the analysis on breast cancer risk indicated increased ORs for AC and CC compared to AA, but this was not statistically significant in the nonstratified results ( Table 4) . The results were not affected by exclusion of subjects with thyroid disease or thyroid medication.
Results were similar in the analysis performed only on subjects genotyped at the Broad Institute and in the analysis limited to invasive breast cancer patients.
SNPs related to fT4 levels in relation to breast cancer risk, stratified by fT4 level For rs6485050 (NR gene), the results indicated a lower breast cancer risk for women with the TC or CC genotype compared to TT in those with low fT4 levels, whereas an opposite association was observed in those with high fT4 levels, Table 5 . This interaction showed a p value of 0.057, which was the only result close to statistical significance in the interaction analysis. For rs2235544 (D101 gene), C allele carrier status was associated with an increased breast cancer risk compared to the AA variant in women with low fT4 levels; in women with high fT4 levels the association was observed for AC. For rs7240777 (NET01 and FBX015 genes), there was a tendency toward a higher breast cancer risk in women with high fT4 levels and the GG variant.
Genetic risk score and variation in traits for fT4-related SNPs
For the 3 fT4-related variants found on a European population, the wGRS showed a statistically significant association in relation to fT4 levels (OR 1.16, 95% CI 1.05-1.28), calculated on the 1189 cases and controls with available fT4 levels. The wGRS for fT4 also indicated that fT4-related SNPs may influence breast cancer risk in women with low fT4 levels (OR 0.90, 95% CI 0.81-1.00) but not in women with high fT4 levels (OR 1.04, 95% CI 0.89-1.21). In the nonstratified analysis, that is, women with both low and high fT4 levels, including all 4058 cases and controls included in this article, there was no association (OR 1.00, 95% CI 0.94-1.07). Rs2235544 (D101 gene) may explain a majority of the wGRS results, as it has one of the highest beta coefficients in the previous study, and had the highest individual contribution to the trait.
A combined wGRS of the 3 SNPs related to fT4 levels explained 2.0% of the variation in fT4 levels in the 606 cases, 0.3% in the 583 controls and 1.0% calculated on 1189 cases and controls. The wGRS did not explain any of the breast cancer risk in the unstratified analysis and only 0.1% in women with high fT4 levels. However, it explained 0.7% of variation in breast cancer risk in women with low fT4 levels. There was higher contribution from rs2235544 (D101 gene) than from the combined weighted GRS. For instance, 2.2% of fT4 levels and 1.1% of breast cancer risk in women with low fT4 levels were due to rs2235544 (D101 gene).
Discussion
In this study, we used previously reported genetic markers for TPO-Ab positivity and free T4 levels to test the potential association between thyroid function and breast cancer risk. The main findings were that fT4-related SNPs rs2235544 and rs6485050 and TPO-Ab-related SNPs rs11675434, rs3094228, Abbreviation: NR, not registered. 1 Major allele was used as reference for all SNPs. Minor allele frequency (MAF) was >5% for all SNPs. 2 Crude odds ratio. 3 Odds ratio adjusted for age at baseline, time of baseline examination, menopausal status, socioeconomic index, education, marital status, country of birth, hormonal replacement therapy, oral contraception, age at menarche, parity, body mass index, alcohol consumption and smoking.
rs1033662, rs301806 and rs2071403 may be associated with breast cancer risk, of which rs2235544 (D101) showed the most promising potential of a causal relationship. To our knowledge, no previous studies have been conducted on thyroid-related SNPs and breast cancer risk. Previous cross-sectional studies on thyroid disease and BC risk have been inconclusive, illustrated by some recent reviews. [28] [29] [30] [31] [32] However, a recently published population-based study on 142,216 women diagnosed with thyroid disease found hyperthyroidism to increase incident BC risk and hypothyroidism to slightly decrease BC risk. 33 In addition, the majority of prospective studies on thyroid analytes have indicated an association with BC risk, although there are still no conclusive results. 10, 12, [34] [35] [36] [37] Regarding our studied analyte fT4, our research group and another large prospective study have recently shown that high fT4 was associated with an increase in BC risk 10,37 but a smaller prospective study reported low fT4 to be related to an increased BC risk. 35 For TPO-Ab, cross-sectional studies have found a correlation between presence of TPO-Ab and BC, as reviewed by Hardefeldt et al., 32 and our previous study indicated that prediagnostic TPO-Ab positivity decreases BC risk. 10 One of the most interesting findings in this study was regarding fT4-related SNP rs2235544 (D101), where the C allele was associated with a lower fT4 level, in the heterozygote, homozygote, and per allele analysis as well as with an increased breast cancer risk. The results regarding free T4 levels are in line with the previous study by Panicker et al. Abbreviations: NR, not registered; N 5 number of subjects. 1 Major allele was used as reference for all SNPs. Minor allele frequency (MAF) was >5% for all SNPs. 2 Crude odds ratio. 3 Odds ratio for high free T4 level adjusted for age at baseline, time of baseline examination and smoking. 4 Odds ratio and p values for breast cancer adjusted for age at baseline, menopausal status, socioeconomic index, education, marital status, country of birth, hormonal replacement therapy, oral contraception, age at menarche, parity, body mass index, alcohol consumption and smoking. p values are only displayed for the per allele analysis.
Rs2235544 is located in the D101 gene, which regulates the deiodinase type 1 enzyme, which is responsible for T4 to triiodothyronine (T3) conversion. 38, 39 The association with breast cancer risk was especially apparent among women with low levels of fT4, that is, the C allele would lead to lower fT4 levels and a higher breast cancer risk, possibly through a higher conversion from T4 to active thyroid hormone T3. A previous study has also shown a higher activity of D101 in breast cancer cells than in normal breast tissue. 40 For another fT4-related SNP rs6485050 (NR gene, SNAP Proxy for rs7951105), the results indicated a lower breast cancer risk in women with low fT4 levels, whereas there was a suggested association of higher breast cancer risk in those with high fT4 levels. Consequently, fT4 level could possibly be an effect modifier in the association between rs6485050 and breast cancer. There is no registered gene for this SNP and the possible biological function behind this is therefore unknown.
The most interesting TPO-Ab-related SNPs in our study were rs11675434, rs2071403, rs3094228, rs1033662 and rs301806. Both rs11675434 and rs2071403 are nearby the TPO gene. With TPO catalyzing key reactions in thyroid hormone synthesis and mutations in TPO being linked to hypothyroidism, 22 these SNPs have a clear biological association with thyroid function. For rs11675434, the T allele has previously been associated with TPO-Ab positivity. 22 Our results also showed a tendency toward this and the T allele was associated with an increased breast cancer risk. For rs2071403, Kwak et al. showed an association between the A allele and a lower risk of TPO-Ab positivity in Korean 3 Odds ratio adjusted for age at baseline, time of baseline examination, menopausal status, socioeconomic index, education, marital status, country of birth, hormonal replacement therapy, oral contraception, age at menarche, parity, body mass index, alcohol consumption and smoking. 4 p values for this interaction was 0.057.
subjects. 23 In our study, the results were unclear but pointed in the same direction. Also, there was a suggested association between the A allele and a decreased risk of breast cancer in the stratified analysis. For rs3094228 (HCP5 gene), Medici et al. showed an association between the C allele and TPO-Ab positivity. 22 In our study, we did not find any association between the C allele and TPO-Ab positivity. However, the C allele of rs3094228 was associated with a statistically significant lower breast cancer risk in this study. The HCP5 gene is within the Human Leukocyte Antigen Complex and part of the immune system. Also, the rs3094228 has previously been associated with the autoimmune thyroid disease Grave's Disease.
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Rs1033662 (NR gene, SNAP Proxy for rs4811340 that is near TSHZ2) was associated with a lower BC risk. This was especially apparent in TPO-Ab-positive women, which is interesting as we showed in a previous study that TPO-Abpositive women had a lower BC risk.
10 Rs1033662 has no registered gene, but is in high linkage disequilibrium with rs4811340, which has been shown to be within 1 Mb distance from TSHZ2, 42 a gene downregulated in breast cancer cells and related to development and progression of breast cancer. 43 For rs301806 (RERE gene, SNAP proxy for rs301799), the C allele had a suggested association with TPO-Ab positivity. Also, the C allele was statistically significantly associated with risk of breast cancer, especially in TPO-Ab-negative women. Similar to the other associations that were more apparent in TPO-Ab-negative women than in TPO-Ab-positive women, the results may be affected by a higher number of women having a negative TPO-Ab status. Rs301806 is located near RERE gene in the distal region of chromosome 1. 22, 45 Structural rearrangements in this genomic region have been linked to several malignancies, including neuroblastoma and colorectal cancer, and the region is thought to contain tumor suppressor genes. 44 Hence, it may be that this SNP affects breast cancer risk both through its effect on TPO-Ab positivity and through its direct effect on breast cancer risk through being nearby tumor suppressor genes. Strengths of this study include a 99% completeness of the registers used to identify breast cancer patients versus controls. 16 Also, patients and controls were from the same Swedish city and therefore there was a genetic homogeneity between patients and controls.
As the study was hypothesis-based, a statistical significance limit of 95% CI was applied and no correction was used, to avoid false negatives. However, there is still a risk of false-negative results in the analysis with outcome thyroid analyte levels (potentially due to not enough statistical power and associations in the expected direction) and false-positive results in the analysis with outcome breast cancer (due to multiple testing and no previous results to compare to and no replication in this study). There is also a possibility that the effects of the SNPs in our study are from nearby SNPs in high linkage disequilibrium, for instance, rs3094228 is in an area with high linkage disequilibrium. 45 Mendelian Randomization has some assumptions to be able to display a causal relationship. 6 First, the genetic variants should be associated with the exposure, in our case the SNPs should be related with TPO-Ab positivity and fT4 levels. The SNPs in our study have all previously been associated with TPO-Ab levels and fT4 levels in large genome-wide association studies. In this study, the wGRS for TPO-Ab-and fT4-related SNPs were associated with thyroid analyte levels but in the individual SNP analysis several of our SNPs were more related to breast cancer than with levels. Further replication studies would be useful to conclude the relationship between these SNP and thyroid analyte levels, with available fT4 and TPO Ab levels for a higher number of patients.
Second, the genetic markers should also be independent of the outcome itself, to be a marker for the exposure's effect on the outcome. Third, a biological role of the nearby gene strengthens the assumption of a causal relationship in Mendelian Randomization. Some of the SNPs in this study have previously been associated with thyroid function (the exposure) independent of the outcome breast cancer and have a biological role of the nearby gene, for example, rs2235544 (D101) and rs11675434 (TPO). For rs11675434 (TPO) though, the association was stronger with breast cancer risk than TPO-Ab positivity in this study.
Hence, the most exciting result in this study and with the highest potential to show a causal relationship through Mendelian Randomization was for rs2235544 (D101). Rs2235544 (D101) was both associated with free T4 levels and with breast cancer risk (especially in the results stratified for fT4 level), and D101 has a clear biological association with thyroid function as well as a higher activity in breast cancer cells than normal breast cells. However, as this is the first study to report an association with breast cancer risk, these results have to be confirmed in larger sample sizes. Several of the other SNPs in this study also showed promising results of replicating previous findings in regards to TPO-Ab positivity and fT4 level, with associations in the expected direction. Some of them were also associated with breast cancer risk, including TPO-Ab-related SNPs rs11675434, rs3094228, rs1033662 and rs301806. This is the first study to show an association between thyroid-related SNPs and breast cancer risk. The SNPs were nearby genes related to thyroid function, the immune system and/or thought to contain tumor suppressors. Hence, they have a biological plausibility of affecting breast cancer risk either directly or through influencing thyroid analyte levels. The association between thyroid function and breast cancer is likely complex, as thyroid function affects the metabolism of all cells, including cancer cells and the immune system cells fighting it. Furthermore, it may be difficult to determine thyroid function only through blood samples taken at one or a few times (even though individual thyroid analyte levels are relatively stable over time). We believe that the genetic variants may be a better marker for life long thyroid function than a single test of levels. Therefore, future detailed studies including more SNP studies (in which the marker for thyroid function is constant over time) and thyroid receptor studies, in combination with thyroid analyte levels, may provide a clearer picture of the association between thyroid function and breast cancer risk. Moreover, additional hypothesis based studies on the association between SNPs and breast cancer risk may increase the knowledge of relevant genetic risk factors for breast cancer.
